

Clinical trials of Inogatran

TrialResults-center www.trialresultscenter.org

1 acute coronary syndrome

Trial	Treatments	Patients	Trials design and methods
Inogatran vs heparin			
TRIM, 1997 n=1209 follow-up: 30 days	Inogatran 0.15.5 mg bolus; 2.010.0 mg/h infusion for 72h versus UFH 5000 IU bolus; 1200 IU/h infusion	patients with suspected unstable angina, or non-Q wave myocardial infarction	Parallel groups double blind

More details and results :

- antithrombotics for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q24>

References

TRIM, 1997:

A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group. Eur Heart J 1997;18:1416-25 [[9458447](#)]

Entry terms: inogatran, inogatran, N-(2-(2-(((3-((aminoiminomethyl)amino)propyl)amino)carbonyl)-1-piperidinyl)-1-(cyclohexylmethyl)-2-oxo-ethyl)glycine, H 314-27, H314-27, H-314-27,